艾斯特拉泽内卡的肺癌药物试验失败导致股份下跌5%, AstraZeneca's lung cancer drug trial failure leads to 5% share dip and FDA approval doubts.

阿斯利康（AstraZeneca）的股价下跌5%，至121.10英镑，此前其肺癌药物datopotamab deruxtecan的试验结果令人失望。 AstraZeneca's shares fell 5% to 121.10 pounds following disappointing trial results for its lung cancer drug, datopotamab deruxtecan. 该药物原打算用于治疗先进的非典型非小型细胞肺癌,但总体存活率没有显著提高。 The drug, intended for advanced nonsquamous non-small cell lung cancer, failed to show significant improvement in overall survival rates. 这种挫折使人们对美国食品药品监督管理局 (FDA) 的潜在批准产生了疑虑,并影响了FTSE 1000指数. This setback raises doubts about its potential approval by the U.S. Food & Drug Administration and affects the FTSE 1000 index.